Cosentyx (secukinumab subcutaneous injection – Novartis) — Cigna

Initial criteria

• Patient is age ≥ 4 years
• Medication is prescribed by or in consultation with a rheumatologist

Reauthorization criteria

• Patient has been established on Cosentyx subcutaneous for at least 6 months
• Patient meets at least ONE of the following: (a) Objective measure shows beneficial clinical response from baseline; OR (b) Improvement in ≥ 1 symptom such as less joint pain or tenderness, improved function, decreased morning stiffness or fatigue

Approval duration

6 months initial, 1 year reauth